In recent years cancer has cancer has emerged as a major public health problem in the world and a few of the most common forms are breast cancer, lung cancer, prostate cancer and leukemia. Antibody drug conjugates (ADCs) signify a promising and an efficient strategy for targeted cancer therapy. ADCs are being developed as a new class of highly potent bio-pharmaceutical drugs, and characterized as an advanced therapeutic application that has collective properties of monoclonal antibodies (mAbs) with the potent small molecule drugs (cytotoxin). At present times, as research, development and approval of ADC-based technology moves forward, ADC-based chemotherapy drugs will impact the current chemotherapy market. It is further expected to improve the quality of life for cancer patients and influence research and development in other pharmaceutical markets.
The factor which is significantly boosting the growth of the global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies market is the rise in the incidence of cancer coupled with growing geriatric population. The increase in obese population and increasing research activities on antibody therapies is catalyzing the growth of Antibody drug conjugates industry. Also, increased investments by governments and private organizations for the preclinical research, and the cumulative research on oncology diseases are contributing to the growth of the global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies market. Increased focus of medical professionals on development of alternative therapies and treatments owing to the continually growing prevalence of cancer is projected to create growth opportunities during the forecast period.
The Global Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies market is categorized on the basis of ADC Linker Technologies, ADC Conjugation Technologies, application and region. On the basis of ADC Linker Technologies type, the market is segmented into Non-cleavable Linkers and Cleavable Linkers. Based on ADC Conjugation Technologies type, the market is segmented into Chemical Conjugation, and Enzymatic Conjugation. On the basis of application, the market is segmented into Leukemia, Lymphoma, Breast Cancer, Ovarian Cancer, Lung Cancer, and Brain Tumor. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, Asia-Pacific is expected to dominate the market during the analysis of forecast period.
The key players of this market include Seattle Genetics, Inc., ImmunoGen, Ambrx, Catalent Biologics, Immunomedics, Mersana Therapeutics, Sutro Biopharma, Iksuda Therapeutics, LegoChem Biosciences, LinXis, ADC therapeutics and Other Prominent Players.